Business Description
Aeolus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00765G1094
Compare
Compare
Traded in other countries / regions
AOLS.USA IPO Date
1996-02-02Description
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -434.89 | |||||
OCF Margin % | -434.89 |
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AOLS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aeolus Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.771 | ||
| EPS (TTM) ($) | -0.04 | ||
| Beta | -134.2398 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 1.04 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 0.0001 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.0001 - 0.0001 | ||
| Shares Outstanding (Mil) | 152.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aeolus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aeolus Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2004-07-16 | 2.40 (+9.09%) |
Show
Entries
Aeolus Pharmaceuticals Inc Frequently Asked Questions
What is Aeolus Pharmaceuticals Inc(AOLS)'s stock price today?
The current price of AOLS is $0.00. The 52 week high of AOLS is $0.00 and 52 week low is $0.00.
When is next earnings date of Aeolus Pharmaceuticals Inc(AOLS)?
The next earnings date of Aeolus Pharmaceuticals Inc(AOLS) is .
Does Aeolus Pharmaceuticals Inc(AOLS) pay dividends? If so, how much?
Aeolus Pharmaceuticals Inc(AOLS) does not pay dividend.
Guru Commentaries on OTCPK:AOLS
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Aeolus Announces Commencement of Assignment for the Benefit of Creditors | 2019-04-11 |
Articles on Aeolus Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers